臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 总笔数 :2815035
	造访人次 : 27383983 在线人数 : 528 教育部委托研究计画计画执行:国立台湾大学图书馆

搜寻范围

进阶搜寻

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"clancy j s"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 1-8 / 8 (共1页)
1
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2022-09-15T01:09:04Z	Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial	Shaw A.T.; Solomon B.J.; Chiari R.; Riely G.J.; Besse B.; Soo R.A.; Kao S.; Chia-Chi Lin; Bauer T.M.; Clancy J.S.; Thurm H.; Martini J.-F.; Peltz G.; Abbattista A.; Li S.; Ou S.-H.I.
臺大學術典藏	2022-09-15T01:08:57Z	Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer	Peters S.; Shaw A.T.; Besse B.; Felip E.; Solomon B.J.; Soo R.A.; Bearz A.; Gadgeel S.M.; Chia-Chi Lin; Kao S.; Seto T.; Masters E.T.; Abbattista A.; Clancy J.S.; Thurm H.; Reisman A.; Peltz G.; Ross Camidge D.
臺大學術典藏	2020-05-25T07:35:09Z	Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC)	Peters S; Shaw A.T; Besse B; Felip E; Solomon B.J; Soo R.A; Bearz A; Gadgee S.M; Chia-Chi Lin; Kao S; Seto T; Masters E.T; Abbattista A; Clancy J.S; Thurm H; Reisman A; Camidge D.R.
臺大學術典藏	2020-05-25T07:35:07Z	ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non�Vsmall-cell lung cancer	Shaw A.T; Solomon B.J; Besse B; Bauer T.M; Chia-Chi Lin; Soo R.A; Riely G.J; Ignatius Ou S.-H; Clancy J.S; Li S; Abbattista A; Thurm H; Satouchi M; Camidge D.R; Kao S; Chiari R; Gadgeel S.M; Felip E; Martini J.-F.
臺大學術典藏	2020-05-25T07:35:07Z	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study	Solomon B.J; Shaw A.T.; Ignatius Ou S.-H; Thurm H; Peltz G; Besse B; Bauer T.M; Felip E; Soo R.A; Camidge D.R; Chiari R; Bearz A; Chia-Chi Lin; Gadgeel S.M; Riely G.J; Tan E.H; Seto T; James L.P; Clancy J.S; Abbattista A; Martini J.-F; Chen J
臺大學術典藏	2020-05-25T07:34:59Z	Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer	Peters S; Shaw A.T; Besse B; Felip E; Solomon B.J; Soo R.A; Bearz A; Gadgeel S.M; Chia-Chi Lin; Kao S; Seto T; Masters E.T; Abbattista A; Clancy J.S; Thurm H; Reisman A; Peltz G; Ross Camidge D.
臺大學術典藏	2019	Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1�V2 trial	Ou S.-H.I.;Li S;Abbattista A;Peltz G;Martini J.-F;Thurm H;Clancy J.S;Bauer T.M;Chia-Chi Lin;Kao S;Soo R.A;Besse B;Riely G.J;Chiari R;Solomon B.J;Shaw A.T; Shaw A.T; Solomon B.J; Chiari R; Riely G.J; Besse B; Soo R.A; Kao S; Chia-Chi Lin; Bauer T.M; Clancy J.S; Thurm H; Martini J.-F; Peltz G; Abbattista A; Li S; Ou S.-H.I.
臺大學術典藏	2019	Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1�V2 trial	Ou S.-H.I.;Li S;Abbattista A;Peltz G;Martini J.-F;Thurm H;Clancy J.S;Bauer T.M;Chia-Chi Lin;Kao S;Soo R.A;Besse B;Riely G.J;Chiari R;Solomon B.J;Shaw A.T; Shaw A.T; Solomon B.J; Chiari R; Riely G.J; Besse B; Soo R.A; Kao S; Chia-Chi Lin; Bauer T.M; Clancy J.S; Thurm H; Martini J.-F; Peltz G; Abbattista A; Li S; Ou S.-H.I.

显示项目 1-8 / 8 (共1页)
1
每页显示[10|25|50]项目